이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

TPST-1495 in Patients With Familial Adenomatous Polyposis

2026년 11월 18일 업데이트: National Cancer Institute (NCI)

가족성 선종성 폴립증(FAP) 환자를 대상으로 TPST-1495의 효능과 안전성을 평가하기 위한 2상 연구

This open-label phase II trial tests how well TPST-1495 works in reducing the number of polyps in the small bowel and colon in patients with familial adenomatous polyposis (FAP). FAP is an inherited condition in which numerous polyps (growths that protrude from mucous membranes) form on the inside walls of the colon and rectum. It increases the risk for colon cancer. TPST-1495 binds to specific prostaglandin receptors. TPST-1495 is a dual antagonist of the prostaglandin E2 (PGE2) receptor subtypes EP2 and EP4, while sparing the immune-stimulating EP1 and EP3 receptors. TPST-1495 may help reduce the number of polyps in the small bowel and colon in patients with FAP.

연구 개요

상세 설명

PRIMARY OBJECTIVES:

I. To assess the activity of TPST-1495 in reducing duodenal polyp burden in patients with FAP.

II. To assess the safety of TPST-1495 in patients with FAP; we will evaluate the incidence of grade 2 or 3 adverse events.

SECONDARY OBJECTIVE:

I. The activity of TPST-1495 in reducing rectum/IPAA (ileal pouch-anal anastomosis) polyp burden in patients with FAP.

EXPLORATORY OBJECTIVES:

I. Reduction in intestinal polyp burden as a function of immunohistochemical staining at baseline and end of intervention (6-months) of rectal and duodenal tissue samples for COX-2 expression level, beta-catenin, and Ki-67.

II. Proteomic profile of serum correlated to clinical response to therapy compared between baseline and end of intervention.

III. Biospecimen acquisition.

OUTLINE:

Patients receive TPST-1495 orally (PO) once daily (QD) for 6 months in the absence of unacceptable toxicity. Patients also undergo esophagogastroduodenoscopy (EGD) and gastrointestinal (GI) endoscopy with biopsy at baseline and end of treatment and undergo blood sample collection throughout the study.

After completion of study treatment, patients are followed up at 1 month.

연구 유형

중재적

등록 (추정된)

38

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Arizona
      • Phoenix, Arizona, 미국, 85054
        • 모병
        • Mayo Clinic Hospital in Arizona
        • 연락하다:
        • 수석 연구원:
          • Niloy J. Samadder
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • 아직 모집하지 않음
        • Mayo Clinic in Rochester
        • 수석 연구원:
          • Lisa A. Boardman
        • 연락하다:
    • Utah
      • Salt Lake City, Utah, 미국, 84112
        • 아직 모집하지 않음
        • Huntsman Cancer Institute/University of Utah
        • 연락하다:
        • 수석 연구원:
          • Jessica R. Stout
    • Wisconsin
      • Madison, Wisconsin, 미국, 53792
        • 모병
        • University of Wisconsin Carbone Cancer Center - University Hospital
        • 수석 연구원:
          • Lisa M. Barroilhet
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Diagnosis of familial adenomatous polyposis (FAP), defined as at least one of the following:

    • Genetic diagnosis with confirmed APC mutation (clinical CLIA [clinical laboratory improvement amendments] certified lab or research testing)
    • Obligate carrier
    • Clinical diagnosis of classic FAP with ≥ 100 colorectal adenomas status post colectomy or a sub-total colectomy and a family history of FAP
    • Clinical diagnosis of FAP, based on personal and family history. Note: This criterion requires documented review and agreement from either the study chair or the MW consortium lead investigator
  • Previously underwent prophylactic colectomy or sub-total colectomy with IRA (ileo-rectal or ileo-colonic anastomosis) or IPAA at least 12 months before pre-registration evaluation and without ongoing surgical complication

  • Willing to discontinue taking non-steroidal anti-inflammatory drugs (NSAIDs) 5 days prior to initiation of study treatment and limit frequency of NSAID dosing during study treatment

  • Age ≥ 18. Because no dosing or adverse event (AE) data are currently available on the use of TPST-1495 in participants < 18 years of age, children and adolescents are excluded from this study but will be eligible for future pediatric trials, if applicable

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)

  • Leukocytes (white blood count [WBC]) ≥ 3,000/uL (≥ 2,500/uL for African American participants)

  • Platelet count ≥ 100 x 10^9/L

  • Hemoglobin ≥ 11.5 g/dL

  • Total bilirubin ≤ 1.5 x institutional upper limit normal (ULN) (unless patient has Gilbert's)

  • Alkaline phosphatase ≤ 1.5 x institutional ULN

  • Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) ≤ 2 x institutional ULN

  • Alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) ≤ 2 x institutional ULN

  • Creatinine ≤ institutional ULN

  • Urinary testing results within institutional limits of normal or deemed clinically insignificant

  • Individuals on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible

  • Presence of Spigelman 2 or 3 duodenal polyposis stage assessed by endoscopy

  • Not pregnant: The effects of TPST-1495 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation or for 90 days after stopping study agent. Additionally, men should not donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose of study agent. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately

  • Not currently breastfeeding

  • Ability to understand and the willingness to sign a written informed consent document

  • Helicobacter (H.) pylori negative confirmed with gastric biopsy (at time of screening EGD) as the preferred option. If gastric biopsies are not available or collected, sites can consider non-invasive testing options for H. pylori such as stool antigen or breath testing and invoice for that test if performed. If H. pylori status was previously assessed within 30 days of the endoscopy we would also accept the results of that test. If positive for H. pylori the patient can be offered full course of approved therapy with confirmation of eradication and re-assessment for trial participation with likely need to repeat baseline endoscopies if > 60 days since date of baseline procedures

Exclusion Criteria:

  • Use of any other investigational agents ≤ 12 weeks prior to pre-registration
  • History of gastric or intestinal ulceration due to NSAID therapy
  • Uncontrolled intercurrent illness or recent surgical procedure that in the opinion of the investigative team would limit compliance with study requirements
  • History of invasive malignancy ≤ 3 years prior to pre-registration (exception: adequately treated carcinoma of the cervix, carcinoma in situ, or basal or squamous cell carcinomas of the skin)
  • History of any upper GI surgery that does not permit access to or evaluation of a 10 cm segment of the duodenum that includes the duodenal bulb, i.e. Whipple procedure or similar
  • Any histologically confirmed high grade dysplasia (HGD) or cancer, gastrointestinal bleeding and requirement for anticoagulation therapy after study start except for use of low dose aspirin
  • Exclusion of patients utilizing strong a moderate inhibitors of CYP2D6 and CYP3A4
  • Individuals with evidence of human immunodeficiency virus (HIV) infection will be excluded from the study even if the HIV viral load is undetectable on suppressive therapy. Many of the HIV suppression anti-viral medications are moderate/strong inhibitors of CYP2D6 and CYP3A4 and are exclusions based on above
  • Individuals with evidence of chronic hepatitis B virus (HBV) or C virus (HCV) infection will be excluded from the study, even if the HBV/HCV viral load is undetectable on suppressive therapy. Many of the HBV/HCV suppression anti-viral medications are moderate/strong inhibitors of CYP2D6 and CYP3A4 and are exclusions based on above
  • Individuals with active H. pylori infection that is untreated or refractory to standard antibiotic therapy
  • Patients with prior history of peptic ulcers complicated by bleeding, New York Heart Association (NYHA) Classification II-IV, active autoimmune diseases, on anticoagulants at risk of bleeding or abnormal corrected QT interval (QTc) prolongation will also be excluded. Patients enrolled in this trial are status post colectomy or subtotal colectomy (with either IPAA or IRA or ileo-colonic anastomosis) and thus would not be expected to be at significant risk of diverticulitis

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 방지
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Prevention (TPST-1495)

Patients receive TPST-1495 PO QD for 6 months in the absence of unacceptable toxicity. Patients also undergo EGD and GI endoscopy with biopsy at baseline and end of treatment and undergo blood sample collection throughout the study.

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Ancillary studies

Undergo biopsy

다른 이름들:
  • 비엑스
  • 생검_유형
  • 생검

Undergo EGD

다른 이름들:
  • EGD
  • 상부 내시경검사

Given PO

다른 이름들:
  • 이중 EP2/4 길항제 TPST-1495
  • PGE2 EP2/EP4 수용체 길항제 TPST-1495
  • 프로스타글란딘 E2 수용체 EP2/EP4 길항제 TPST-1495
  • TPST 1495
  • TPST-1495
  • TPST1495

Undergo GI endoscopy

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Percent change in duodenal polyp burden
기간: Baseline to 6 months

Will be determined based on the sum of diameters from all polyps. Will be assessed by comparing upper gastrointestinal (GI) endoscopies respectively. Will be described using a two-sided 95% confidence interval and examined for difference from zero with a one-side paired t-test.

Baseline to 6 months
Incidence of adverse events
기간: Up to 7 months

Will examine the proportion of patients with grade 2 or 3 adverse events according to the Common Terminology Criteria for Adverse Events version 6.0. Will be summarized as a proportion with a 1-sided 90% confidence interval.

Up to 7 months

2차 결과 측정

결과 측정
측정값 설명
기간
Percent change in rectal/pouch polyp burden
기간: Baseline to 6 months

Will be assessed by comparing the lower GI endoscopies. Results will be presented using summary statistics and corresponding confidence intervals.

Baseline to 6 months

기타 결과 측정

결과 측정
측정값 설명
기간
Percent change in immunohistochemical staining levels
기간: Baseline to 6 months

Will assess rectal and duodenal tissue samples for COX-2 expression level, beta-catenin, and Ki-67. Mean percent change in immunohistochemical staining levels will be associated with intestinal polyp burden using a scatterplot of the two variables and evaluated using a Spearman rank correlation statistic.

Baseline to 6 months
Proteomic profile
기간: Baseline to 6 months

Will identify proteins that are statistically significantly differently expressed between patients after treatment. The proteomic profile of serum will be correlated to clinical response to therapy and compared between baseline and end of intervention. No formal statistical inference will be performed. Proteins will be described with summary statistics to assist in planning follow-up studies.

Baseline to 6 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Niloy J Samadder, University of Wisconsin Carbone Cancer Center - University Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 31일

기본 완료 (추정된)

2027년 6월 30일

연구 완료 (추정된)

2027년 6월 30일

연구 등록 날짜

최초 제출

2024년 8월 15일

QC 기준을 충족하는 최초 제출

2024년 8월 15일

처음 게시됨 (실제)

2024년 8월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 18일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다